Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment

The role of ventricular–arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association

(2019) Ignatios Ikonomidis et al.   EUROPEAN JOURNAL OF HEART FAILURE

Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients

(2019) Roni Nielsen et al.   CIRCULATION

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

(2019) Thomas A. Zelniker et al.   CIRCULATION

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

(2019) Carlos G. Santos-Gallego et al.   CARDIOVASCULAR DRUGS AND THERAPY

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

(2019) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

(2019) Milton Packer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow–Up Study

(2019) Vaia Lambadiari et al.   Journal of Clinical Medicine

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

(2019) Subodh Verma et al.   CIRCULATION

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes

(2019) Vinay Garg et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Correlation between non-invasive myocardial work indices and main parameters of systolic and diastolic function: results from the EACVI NORRE study

(2019) Roberta Manganaro et al.   European Heart Journal-Cardiovascular Imaging

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes

(2018) Vaia Lambadiari et al.   Cardiovascular Diabetology

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

(2018) María Isabel del Olmo-Garcia et al.   Journal of Diabetes Research

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Pulse wave velocity to global longitudinal strain ratio in hypertension

(2018) Ignatios Ikonomidis et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

(2017) Tsung-Ming Lee et al.   FREE RADICAL BIOLOGY AND MEDICINE

Early detection of left ventricular dysfunction in first-degree relatives of diabetic patients by myocardial deformation imaging: The role of endothelial glycocalyx damage

(2017) Ignatios Ikonomidis et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target

(2017) Alessandra Di Franco et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study

(2017) Tadafumi Sugimoto et al.   European Heart Journal-Cardiovascular Imaging

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

(2017) Ioanna Andreadou et al.   Frontiers in Physiology

Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization

(2017) Hertzel C. Gerstein et al.   CIRCULATION

The Cardiovascular Biology of Glucagon-like Peptide-1

(2016) Daniel J. Drucker   Cell Metabolism

Clinical Update: Cardiovascular Disease in Diabetes Mellitus

(2016) Cecilia C. Low Wang et al.   CIRCULATION

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials

(2016) Markolf Hanefeld et al.   Diabetes Therapy

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials

(2016) Markolf Hanefeld et al.   Diabetes Therapy

Similarities in Coronary Function and Myocardial Deformation Between Psoriasis and Coronary Artery Disease: The Role of Oxidative Stress and Inflammation

(2015) Ignatios Ikonomidis et al.   CANADIAN JOURNAL OF CARDIOLOGY

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

(2015) R. Chilton et al.   DIABETES OBESITY & METABOLISM

Increased Benefit of Interleukin-1 Inhibition on Vascular Function, Myocardial Deformation, and Twisting in Patients With Coronary Artery Disease and Coexisting Rheumatoid Arthritis

(2014) Ignatios Ikonomidis et al.   Circulation-Cardiovascular Imaging

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Damage of the Endothelial Glycocalyx in Dialysis Patients

(2012) C. A. Vlahu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation

(2011) John Lekakis et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION